On October 14, 2016, ONC released the final rule entitled ONC Health IT Certification Program: Enhanced Oversight and Accountability. The final rule outlines ONC’s plan for implementing enhanced oversight of certified health IT products via direct review. Health IT Now created a summary table of provisions of the proposed rule and correlating provisions of the final rule.
Home / Resources
On July 14, the House Appropriations Committee approved the Labor, Health & Human Services, Education and Related Agencies (Labor-HHS) funding bill for Fiscal Year (FY) 2017. A number of health IT provisions were included, of which HITN created a summary.
On April 27, 2016 CMS released the proposed rule entitled Medicare Program; Merit-Based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Incentive under the Physician Fee Schedule, and Criteria for Physician-Focused Payment Models.
Health IT Now released a background document on the Precision Medicine Initiative and Cancer Moonshot.
Health IT Now submitted a comment letter to Senate Finance Committee with recommendations for the improvement of care that Medicare patients with chronic conditions receive. We believe that health information is a crucial component in coordinating the care, reduced costs and standardized systems required to improve health outcomes.
The Health IT Now Coalition compiled a summary of H.R. 2, the Medicare Access and CHIP Reauthorization Act of 2015. The full document can be found here.
Health IT Now submitted a comment letter to Chairman Fred Upton and the House Committee on Energy and Commerce regarding the 21st Century Cures Initiative. We are convinced technology must play a foundational role in fostering 21st Century cures. Many aspects of our current health care system encourage inefficiency and promote waste aided and abetted by program and data silos.
Health IT Now sent a comment letter to Congressman Blackburn and Congressman Green on the revised SOFTWARE draft. HITN believes the Committee has substantial opportunities to promote innovation by clearly defining the products subject to FDA review and those products that are not. The latest draft is the clearest, best written bill on the subject we have seen to date.